New horizons in the development of antiepileptic drugs

Epilepsy Research

Volumn 50, Issue 1-2, 2002, Pages 3-16

  Löscher, Wolfgang ^a   Schmidt, Dieter ^b  

^a UNIVERSITY OF VETERINARY MEDICINE HANNOVER   (Germany)

^b Epilepsy Research Group   (Germany)

Author keywords

Antiepileptic drugs; Epileptogenesis; Gene therapy; Neurostimulation; Neurotransplantation; Pharmacoresistance; Seizures

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; ETIRACETAM; GABAPENTIN; LAMOTRIGINE; PENTETRAZOLE; PHENOBARBITAL; PHENYTOIN; TIAGABINE; TOPIRAMATE; VALPROIC ACID; VIGABATRIN;

ANAMNESIS; CONFERENCE PAPER; DISEASE COURSE; DISEASE RESISTANCE; DRUG BIOAVAILABILITY; EPILEPSY; HEAD INJURY; HUMAN; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RASH; RISK FACTOR;

ANIMALS; ANTICONVULSANTS; BRAIN; DISEASE PROGRESSION; DRUG RESISTANCE; EPILEPSY; HUMANS;

EID: 0036342414     PISSN: 09201211     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0920-1211(02)00063-3     Document Type: Conference Paper

References (88)

1. Epilepsy and the immune system
2. Drug resistance in epilepsy: Role of the blood-brain barrier
3. Treatment of epilepsy: Existing therapies and future developments
4. Partial seizures associated with antiphospholipid antibodies in childhood
5. Causes of epilepsy: Contributions of the Rochester epidemiology project
6. Advances in the medical treatment of epilepsy
7. Cell replacement therapies for central nervous system disorders
8. Analysis of the 'honey moon effect' in adult epilepsy patients
9. Comparison of valproate and phenobarbital treatment after status epilepticus in rats
10. Novel treatments for bipolar disorder
11. Gene expression analysis by massively parallel signature sequencing (MPSS) on microbead arrays
12. In vitro cloning of complex mixtures of DNA on microbeads: Physical separation of differentially expressed cDNAs
13. Do we need any more new antiepileptic drugs?
14. Epilepsy
15. Epilepsy-associated plasticity in gamma-aminobutyric acid receptor expression, function, and inhibitory synaptic properties
16. The process of epileptogenesis: A pathophysiological approach
17. Patients with refractory seizures
18. Delayed sclerosis, neuroprotection and limbic epileptogenesis after status epilepticus in the rat
19. Surgical treatment of epilepsy
20. Detecting genes in new and old mouse models for epilepsy: A prospectus through the magnifying glass
21. Distribution of valproate across the interface between blood and cerebrospinal fluid
22. Preventing post-traumatic epilepsy after brain injury: Weighing the costs and benefits of anticonvulsant prophylaxis
23. From transcriptome analysis to validated target genes: Implications of Homer 1A in epileptogenesis
24. Expression of multidrug resistance-associated protein (MRP) in brain microvessel endothelial cells
25. Grafts of adenosine-releasing cells suppress seizures in kindling epilepsy
26. Homer proteins regulate coupling of group I metabotropic glutamate receptors to N-type calcium and M-type potassium channels
27. ABC drug transporters: Hereditary polymorphisms and pharmacological impact in MDR1, MRP1 and MRP2
28. Functional implications of Homer 1a overexpression in transgenic mice for seizure susceptibility
29. Early identification of refractory epilepsy
30. Anticipation of epileptic seizures from standard EEG recordings
31. Ketogenic diet for the treatment of refractory epilepsy in children: A systematic review of efficacy
32. Ion channels and epilepsy
33. From MDR to MXR: New understanding of multidrug resistance systems, their properties and clinical significance
34. Epileptic seizures may begin hours in advance of clinical onset: A report of five patients
35. Animal models of intractable epilepsy
36. New visions in the pharmacology of anticonvulsion
37. Animal models of epilepsy and epileptic seizures
38. Responses to NMDA receptor antagonists altered by epileptogenesis
39. Strategies in antiepileptic drug development: Is rational drug design superior to random screening and structural variation?
40. Role of multidrug transporters in pharmacoresistance to antiepileptic drugs
41. Seizure suppression in kindling epilepsy by grafts of fetal GABAergic neurons in rat substantia nigra
42. The pharmacological basis of contemporary pain management
43. New anti-epileptic drugs for the 21st century
44. Sparing of neuronal function postseizure with gene therapy
45. Emerging insights into the genesis of epilepsy
46. Identification and preclinical testing of novel antiepileptic compounds
47. Withdrawal of antiepileptic medications following epilepsy surgery
48. Single-gene models of epilepsy
49. GABA receptor function and epilepsy
50. Carbamazepine is not a substrate for P-glycoprotein
51. Autoantibodies to glutamic acid decarboxylase in patients with therapy-resistant epilepsy
52. Genetic susceptibility to adverse drug reactions
53. Do the epilepsies, pain syndromes, and affective disorders share common kindling-like mechanisms?
54. Multidrug resistance-associated protein is involved in the regulation of extracellular levels of phenytoin in the brain
55. In vivo evidence for P-glycoprotein-mediated transport of phenytoin at the blood-brain barrier of rats
56. P-Glycoprotein and multidrug resistance-associated protein are involved in the regulation of extracellular levels of the major antiepileptic drug carbamazepine in the brain
57. Recent advances in the genetics of epilepsy: Insights from human and animal studies
58. Choroid plexus epithelial expression of MDR1 P glycoprotein and multidrug resistance-associated protein contribute to the blood-cerebrospinal-fluid drug-permeability barrier
59. Clinical aspects and biological bases of drug-resistant epilepsies
60. Induction of mdr-1 by limbic seizures in mice: Relevance for drug resistance in epilepsy
61. The evolving role of antiepileptic drugs in treating neuropathic pain
62. Porcine fetal GABA-producing neural cell transplants for human partial-onset seizures: Safety and feasibility
63. Genetics of the epilepsies
64. Discontinuation of Antiepileptic drugs after successful epilepsy surgery
65. P-Glycoprotein, a gatekeeper in the blood-brain barrier
66. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs
67. Valproate: Absorption, distribution, and excretion
68. P-Glycoprotein-mediated antiepileptic drug transport: A role in refractory epilepsy?
69. Antiepileptogenic effects of conventional anticonvulsants in the kindling model of epilepsy
70. Over-expression of P-glycoprotein in malformations of cortical development
71. Multidrug-resistance protein 1 in focal cortical dysplasia
72. Drug resistance in epilepsy: Expression of drug resistance proteins in common causes for refractory epilepsy
73. Ion channels and epilepsy in man and mouse
74. Multidrug resistance transporters and modulation
75. Antiepileptogenic agents: How close are we?
76. Conditionally immortalised cell lines, engineered to produce and release GABA, modulate the development of behavioral seizures
77. MDR1 gene expression in brain of patients with medically intractable epilepsy
78. Mechanisms of action of new antiepileptic drugs: Rational design and serendipitous findings
79. Vagus nerve stimulation for seizures
80. Subacute electrical stimulation of the hippocampus blocks intractable temporal lobe seizures and paroxysmal EEG activities
81. Acute and chronic electrical stimulation of the centromedian thalamic nucleus: Modulation of reticulo-cortical systems and predictor factors for generalized seizure control
82. Kindling: Separate vs. shared mechanisms in affective disorders and epilepsy
83. A randomised, controlled trial of surgery for temporal-lobe epilepsy
84. Evaluation of associated behavioral and cognitive deficits in anticonvulsant drug testing
85. Homer: A link between neural activity and glutamate receptor function
86. Induction of P-glycoprotein expression in astrocytes following intracerebroventricular kainate injections
87. Transcranial magnetic stimulation: Its current role in epilepsy research